INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 289 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,683,392 | -1.8% | 53,780 | -0.8% | 0.15% | -3.8% |
| Q1 2024 | $3,752,716 | -29.0% | 54,230 | -26.5% | 0.16% | -33.3% |
| Q4 2023 | $5,285,556 | +37.3% | 73,800 | -0.1% | 0.23% | +19.4% |
| Q3 2023 | $3,849,451 | -21.3% | 73,900 | -4.4% | 0.20% | -11.7% |
| Q2 2023 | $4,894,003 | +273.9% | 77,290 | +219.8% | 0.22% | +246.9% |
| Q1 2023 | $1,308,806 | -59.7% | 24,170 | -60.6% | 0.06% | -62.4% |
| Q4 2022 | $3,247,700 | -20.8% | 61,370 | -30.4% | 0.17% | -25.4% |
| Q3 2022 | $4,103,000 | -20.3% | 88,180 | -2.2% | 0.23% | -17.1% |
| Q2 2022 | $5,147,000 | +108.9% | 90,180 | +123.9% | 0.28% | +159.4% |
| Q1 2022 | $2,464,000 | – | 40,270 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |